Brain cancer survivor Mike Schuster celebrates a milestone he never thought possible.
OKN-007
OMRF doctors make potential breakthrough in brain cancer treatment
Doctors at the Oklahoma Medical Research Foundation are celebrating what could become a breakthrough in brain cancer treatment.
FDA grants designations for OMRF brain tumor drug
The Oklahoma Medical Research Foundation is one step closer to beating rare forms of brain cancers.
OMRF brain tumor drug receives rare disease designations from the FDA
The drug treats fast-growing, deadly brain cancers with no effective treatment.
New use for OMRF brain cancer treatment could extend lives
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
